News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Article

January 7, 2022

Top Five Trends in Life Sciences Compliance for 2022

Author(s):

Company Press Release

Patient protection and social influence among trends to look out for as calendar turns.

Trend 1: Goodbye Doctors, Hello Patients – John Oroho, Executive Vice President and Chief Strategy Officer of Porzio Life Sciences, LLC

Pharmaceutical companies will continue to shift their marketing efforts—and dollars—from healthcare providers to patients. The regulatory structure now in place seeks to protect patients by regulating interactions between drug manufacturers and physicians. As those regulations become more restrictive, manufacturers are increasingly seeking out ways to bypass physicians and connect directly with patients.

Trend 2: Here Come the Influencers – John Oroho, Executive Vice President and Chief Strategy Officer of Porzio Life Sciences, LLC

Social media influencers will continue to become a more significant element of pharmaceutical marketing campaigns. In 2020, the small biotech company Biohaven made Khloe Kardashian a paid spokesperson for its migraine medication, Nurtec ODT. In addition to making appearances on television shows like The View, Kardashian promoted the drug on her social media channels with more than 100 million followers. Weeks later, AbbVie announced Serena Williams as a spokesperson for its competing migraine drug. Williams, too, posted sponsored content on her Instagram.

Trend 3: Regulators Look Abroad – Michelle Axelrod, Senior Vice President of Porzio Life Sciences, LLC

Increasingly, countries are beginning to borrow ideas on transparency regulation from each other. Many countries outside the US have more aggressive reporting criteria on spend transparency, and we can expect some of those requirements to make their way into U.S. law. Senators Chuck Grassley (R-IA) and Ron Wyden (D-OR), for instance, have recommended that pharmaceutical companies be required to report payments made to tax-exempt patient advocacy groups. Likewise, it would not be surprising if the US adopted French rules that require reporting on payments to social media influencers.

Trend 4: Price Transparency Is the New Black – Jennifer A. Romanski, Senior Vice President of Porzio Life Sciences, LLC

Price transparency regulation will continue to proliferate. Transparency regulations in the United States originated with rules on spend transparency, which were enacted with the intent of decreasing drug prices. Rules requiring transparency on, for instance, the amount spent on meals for physicians, did not result in lower prices. Governments have moved on to price transparency regulations as their next most promising avenue to affect drug prices. There are currently 18 states with price transparency regulations in place, and 17 with proposed legislation. It would be a surprise if both numbers did not increase in 2022.

Trend 5: Unintended Consequences Revealed – Michael O’Connor, Senior Vice President and Chief Product Officer of Porzio Life Sciences, LLC

The unintended consequences of price transparency laws should begin to show themselves in 2022. Price transparency regulations in at least 7 states require pharmaceutical companies to reveal information about their marketing activities. That is just one piece of information that pharmaceutical companies have been reluctant to report publicly, for fear of handing valuable business intelligence to their competitors. In 2022, we should begin to see whether that provision or others begin to have any unintended consequences on market behavior.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
August 22nd 2025

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers

Don Tracy, Associate Editor
Cell and Gene Therapy Check-in 2024
August 22nd 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
August 22nd 2025

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities

Don Tracy, Associate Editor
Industry Outlook 2022
August 22nd 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.
August 22nd 2025

How Should BioPharma C-Suites Guide and Support Remaining Employees After Workforce Reductions?

Michael Wong
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 22nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Related Content
Advertisement
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
August 22nd 2025

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers

Don Tracy, Associate Editor
Cell and Gene Therapy Check-in 2024
August 22nd 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
August 22nd 2025

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities

Don Tracy, Associate Editor
Industry Outlook 2022
August 22nd 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.
August 22nd 2025

How Should BioPharma C-Suites Guide and Support Remaining Employees After Workforce Reductions?

Michael Wong
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 22nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.